In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage

Transfusion

Volumn 47, Issue 4, 2007, Pages 653-665

  Apelseth, Torunn O ^a   Bruserud, Øystein ^b   Wentzel Larsen, Tore ^b   Bakken, Anne M ^b   Bjørsvik, Solfrid ^b   Hervig, Tor ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CD61 ANTIGEN; COLLAGEN; GLYCOPROTEIN IB ALPHA; PADGEM PROTEIN; PARAFORMALDEHYDE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOCYTE CONCENTRATE;

ARTICLE; DOWN REGULATION; FLOW CYTOMETRY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOTOCHEMISTRY; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE PRESERVATION;

ADENOSINE DIPHOSPHATE; BLOOD DONORS; BLOOD PLATELETS; BLOOD PRESERVATION; CYTOKINES; ENZYME ACTIVATION; FLOW CYTOMETRY; GAMMA RAYS; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; INTEGRIN BETA3; L-LACTATE DEHYDROGENASE; P-SELECTIN; PHOTOCHEMISTRY; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELETPHERESIS; RECEPTORS, THROMBIN; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 33947365171     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01167.x     Document Type: Article

References (78)

1. Lin L, Hanson CV, Alter HJ, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45:580-90.
2. Wollowitz S. Targeting DNA and RNA in pathogens: mode of action of amotosalen HCl. Transfus Med Hemother 2004;31(Suppl 1):11-6.
3. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-8.
4. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-9.
5. Jansen GA, van Vliet HH, Vermeij H, et al. Functional characteristics of photochemically treated platelets. Transfusion 2004;44:313-9.
6. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44:1732-40.
7. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004;104:1534-41.
8. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
9. Slichter SJ, Raife TJ, Davis K, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006;46:731-40.
10. Tada-Oikawa S, Oikawa S, Kawanishi S. Role of ultraviolet A-induced oxidative DNA damage in apoptosis via loss of mitochondrial membrane potential and caspase-3 activation. Biochem Biophys Res Commun 1998;247:693-6.
11. Bruchmuller I, Losel R, Bugert P, et al. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 2005;16:441-5.
12. Cazenave JP, Aleil B, Wiesel ML, et al. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen. Vox Sang 2004;86:201-2.
13. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86:239-45.
14. Isola H, Kientz D, Aleil B, et al. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set. Vox Sang 2006;90:128-30.
15. Moog R, Frohlich A, Mayaudon V, Lin L. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. J Clin Apher 2004;19:185-91.
16. Metcalfe P, Williamson LM, Reutelingsperger CP, et al. Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997;98:86-95.
17. Snyder EL, Hezzey A, Katz AJ, Bock J. Occurrence of the release reaction during preparation and storage of platelet concentrates. Vox Sang 1981;41:172-7.
18. Rinder HM, Snyder EL, Bonan JL, et al. Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and beta-thromboglobulin release. Transfusion 1993;33:25-9.
19. Wang C, Mody M, Herst R, et al. Flow cytometric analysis of platelet function in stored platelet concentrates. Transfus Sci 1999;20:129-39.
20. Hagberg IA, Akkok CA, Lyberg T, Kjeldsen-Kragh J. Apheresis-induced platelet activation: comparison of three types of cell separators. Transfusion 2000;40:182-92.
21. Lozano ML, Rivera J, Gonzalez-Conejero R, et al. Loss of high-affinity thrombin receptors during platelet concentrate storage impairs the reactivity of platelets to thrombin. Transfusion 1997;37:368-75.
22. Rinder HM, Snyder EL, Tracey JB, et al. Reversibility of severe metabolic stress in stored platelets after in vitro plasma rescue or in vivo transfusion: restoration of secretory function and maintenance of platelet survival. Transfusion 2003;43:1230-7.
23. Vetlesen A, Mirlashari MR, Torsheim IA, Kjeldsen-Kragh J. Platelet activation and residual activation potential during storage of hyperconcentrated platelet products in two different platelet additive solutions. Transfusion 2005;45:1349-55.
24. Leytin V, Allen DJ, Gwozdz A, et al. Role of platelet surface glycoprotein Ibalpha and P-selectin in the clearance of transfused platelet concentrates. Transfusion 2004;44:1487-95.
25. Dumont LJ, AuBuchon JP, Whitley P, et al. Seven-day storage of single-donor platelets: recovery and survival in an autologous transfusion study. Transfusion 2002;42:847-54.
26. Rinder HM, Murphy M, Mitchell JG, et al. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991;31:409-14.
27. Holme S, Sweeney JD, Sawyer S, Elfath MD. The expression of P-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion 1997;37:12-7.
28. Rinder HM, Ault KA. Platelet activation and its detection during the preparation of platelets for transfusion. Transfus Med Rev 1998;12:271-87.
29. Holme S, Heaton A. In vitro platelet ageing at 22 degrees C is reduced compared to in vivo ageing at 37 degrees C. Br J Haematol 1995;91:212-8.
30. Gulliksson H. Defining the optimal storage conditions for the long-term storage of platelets. Transfus Med Rev 2003;17:209-15.
31. Apelseth TO, Hervig TA, Wentzel-Larsen T, Bruserud O. Cytokine accumulation in photochemically treated and gamma-irradiated platelet concentrates during storage. Transfusion 2006;46:800-10.
32. Council of Europe. Guide to preparation, use and quality assurance of blood components. 12th ed. Strasbourg: Council of Europe; 2006. p. 128-9.
33. Hervig T, Haugen T, Liseth K, et al. The platelet count accuracy of platelet concentrates obtained by using automated analysis is influenced by instrument bias and activated platelet components. Vox Sang 2004;87:196-203.
34. Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfus Med Rev 1997;11:130-44.
35. Farrugia A. Platelet size analysis in the quality assurance of platelet concentrates for transfusion. Clin Lab Haematol 1995;17:51-5.
36. Macey MG, Carty E, Webb L, et al. Use of mean platelet component to measure platelet activation on the ADVIA 120 haematology system. Cytometry 1999;38:250-5.
37. Ritchie JL, Alexander HD, Rea IM. Flow cytometry analysis of platelet P-selectin expression in whole blood - methodological considerations. Clin Lab Haematol 2000;22:359-63.
38. Mondoro TH, Shafer BC, Vostal JG. Restoration of in vitro responses in platelets stored in plasma. Am J Clin Pathol 1999;111:693-9.
39. Dumont LJ, VandenBroeke T, Ault KA. Platelet surface P-selectin measurements in platelet preparations: an international collaborative study. Biomedical Excellence for Safer Transfusion (BEST)Working Party of the International Society of Blood Transfusion (ISBT). Transfus Med Rev 1999;13:31-42.
40. Escolar G, White JG. Changes in glycoprotein expression after platelet activation: differences between in vitro and in vivo studies. Thromb Haemost 2000;83:371-86.
41. Clemetson KJ, Clemetson JM. Platelet GPIb-V-IX complex: structure, function, physiology, and pathology. Semin Thromb Hemost 1995;21:130-6.
42. Lundblad RL, White GC 2nd. The interaction of thrombin with blood platelets. Platelets 2005;16:373-85.
43. Hagberg IA, Lyberg T. Blood platelet activation evaluated by flow cytometry: optimised methods for clinical studies. Platelets 2000;11:137-50.
44. Curvers J, van Pampus EC, Feijge MA, et al. Decreased responsiveness and development of activation markers of PLTs stored in plasma. Transfusion 2004;44:49-58.
45. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev 2006;20:1-26.
46. Dale GL, Remenyi G, Friese P. Quantitation of microparticles released from coated-platelets. J Thromb Haemost 2005;3:2081-8.
47. Gear AR. In vitro platelet responses: aggregation. In: Holmsen H, editors. Platelet responses and metabolism. Boca Raton (FL): CRC Press; 1986. p. 98-101.
48. Breddin HK. Can platelet aggregometry be standardized? Platelets 2005;16:151-8.
49. Dalgaard P. Introductory statistics with R. 1st ed. New York: Springer Verlag; 2002. p. 1-267.
50. Pinheiro JC. Mixed-effects models in S and S-plus. 1st ed. New York: Springer Verlag; 2000. p. 1-270.
51. Rinder HM, Smith BR. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion 2003;43:2-6.
52. Janetzko K, Cazenave JP, Kluter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45:1443-52.
53. van der Meer PF, Pietersz RN, Reesink HW. Storage of platelets in additive solution for up to 12 days with maintenance of good in-vitro quality. Transfusion 2004;44:1204-11.
54. Tudisco C, Jett BW, Byrne K, et al. The value of pH as a quality control indicator for apheresis platelets. Transfusion 2005;45:773-8.
55. Rudderow D, Soslau G. Permanent lesions of stored platelets correlate to pH and cell count while reversible lesions do not. Proc Soc Exp Biol Med 1998;217:219-27.
56. Cardigan R, Turner C, Harrison P. Current methods of assessing platelet function: relevance to transfusion medicine. Vox Sang 2005;88:153-63.
57. Goodrich RP, Li J, Pieters H, et al. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006;90:279-85.
58. Gulliksson H, Larsson S, Kumlien G, Shanwell A. Storage of platelets in additive solutions: effects of phosphate. Vox Sang 2000;78:176-84.
59. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
60. Dumont LJ, AuBuchon JP, Gulliksson H, et al. In vitro pH effect on in vivo recovery and survival of platelets: an analysis by the BEST Collaborative. Transfusion 2006;46:1300-5.
61. Bertolini F, Agazzi A, Peccatori F, et al. The absence of swirling in platelet concentrates is highly predictive of poor posttransfusion platelet count increments and increased risk of a transfusion reaction. Transfusion 2000;40:121-2.
62. Kostelijk EH, Fijnheer R, Nieuwenhuis HK, et al. Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost 1996;76:1086-9.
63. Ishiwata N, Takio K, Katayama M, et al. Alternatively spliced isoform of P-selectin is present in vivo as a soluble molecule. J Biol Chem 1994;269:23708-15.
64. Dijkstra-Tiekstra MJ, Pietersz RN, Huijgens PC. Correlation between the extent of platelet activation in platelet concentrates and in vitro and in vivo parameters. Vox Sang 2004;87:257-63.
65. Divers SG, Kannan K, Stewart RM, et al. Quantitation of CD62, soluble CD62, and lysosome-associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates. Transfusion 1995;35:292-7.
66. Ahnadi CE, Sabrinah Chapman E, Lepine M, et al. Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy. Thromb Haemost 2003;90:940-8.
67. Snyder EL, Koerner TA Jr, Hezzey A. Platelet concentrates: influence of different preparative protocols on the in vitro release reaction. Vox Sang 1982;43:71-5.
68. Michelson AD, Benoit SE, Kroll MH, et al. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood 1994;83:3562-73.
69. Michelson AD, Barnard MR, Hechtman HB, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A 1996;93:11877-82.
70. Berger G, Hartwell DW, Wagner DD. P-selectin and platelet clearance. Blood 1998;92:4446-52.
71. Rivera J, Sanchez-Roig MJ, Rosillo MC, et al. Stability of glycoproteins Ib/IX and IIb/IIIa during preparation and storage of platelet concentrates: detection by binding assays with epitope-defined monoclonal antibodies and physiological ligands. Vox Sang 1994;67:166-71.
72. Holme S, Bode A, Heaton WA, Sawyer S. Improved maintenance of platelet in vivo viability during storage when using a synthetic medium with inhibitors. J Lab Clin Med 1992;119:144-50.
73. Keuren JF, Cauwenberghs S, Heeremans J, et al. Platelet ADP response deteriorates in synthetic storage media. Transfusion 2006;46:204-12.
74. Miyaji R, Sakai M, Urano H, et al. Decreased platelet aggregation of platelet concentrate during storage recovers in the body after transfusion. Transfusion 2004;44:891-9.
75. Packham MA, Kinlough-Rathbone RL, Mustard JF. Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987;70:647-51.
76. Packham MA, Mustard JF. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. Semin Thromb Hemost 2005;31:129-38.
77. Simonsen AC, Johansson PI, Conlan MG, et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006;46:424-33.
78. Arnold DM, Heddle NM, Kulczycky M, et al. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion 2006;46:257-64.